UK markets closed

Transgene SA (0OCQ.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
3.0400+0.5500 (+22.09%)
At close: 2:05PM BST
Full screen
Previous close2.4900
Open2.5750
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.5750 - 2.5750
52-week range2.5750 - 2.5750
Volume623
Avg. volumeN/A
Market cap189.616M
Beta (5Y monthly)0.97
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • Business Wire

    Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002

    STRASBOURG, France, September 16, 2021--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces the presentation of data from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas at the European Society for Medical Oncology (ESMO) virtual meeting taking place from September 16-21, 2021.

  • Business Wire

    Transgene Announces Upcoming Investor Meetings

    STRASBOURG, France, September 13, 2021--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces that Management will participate in the upcoming investor events set out below:

  • Business Wire

    Transgene Participates in New Cancer Research Consortium

    STRASBOURG, France & UTRECHT, The Netherlands, September 01, 2021--Regulatory News: Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announces its participation in the launch of PERSIST-SEQ, a new international consortium of academic and industrial leaders in the field of cancer research.